The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Site Search
Showing 1 - 4 of 4 results
News
|
May 3, 2023
|
4 min read
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
News
|
May 9, 2023
|
5 min read
The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
News
|
May 17, 2023
|
2 min read
Revised approach to lung function reporting is shown to be more scientifically accurate and may reduce health disparities.
News
|
April 2, 2024
|
5 min read